progressing

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Breaking New Ground

October has been another strong month for our development team who are continuing to make breakthroughs with the NFT module aspects of Paribus. As we always say it’s never easy to do something that hasn’t been done before, and we’re lucky to have such a talented team of devs conscientiously breaking new ground. Even before our MVP hits the mainnet we’ll be ready to conduct in-house testing of various aspects of our NFT iteration. Frontend This month we’re pleased to announce that several areas of the frontend have completed the

A Strong September

Since our last development update, the team has been making remarkable progress with their work on the NFT module integrations. Not only have the frontend integrations for NFT views been successful they’ve also been progressing well with the datapoint integrations on the backend. Whereas other projects may be going into hibernation during this bear market, we’re excited to confirm that our BUIDLing is progressing at a tremendous pace. Frontend In the last update, we shared that the team was working on how to integrate the NFT views into the frontend.